• 1
    Shields OL, Shields JA. Diagnosis and management of retinoblastoma. Cancer Control 2004; 11: 31727.
  • 2
    Schultz KR, Ranade S, Neglia JP et al. An increased relative frequency of retinoblastoma at a rural regional referral hospital in Miraj Maharashtra, India. Cancer 1993; 72: 2826.
  • 3
    Chantada G, Fandino A, Manzitti J et al. Late diagnosis of retinoblastoma in a developing country. Arch Dis Child 1999; 80: 1714.
  • 4
    Friedman DL, Himelstein B, Shields CL et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000; 18: 127.
  • 5
    Cao W, Tombran-Tink J, Elias R et al. In vivo protection of photoreceptors from light damage by pigmentepithelium-derived factor. Invest Ophthalmol Vis Sci 2001; 42: 164652.
  • 6
    Tombran-Tink J, Chader GG, Johnson LV. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 1991; 53: 4114.
  • 7
    Ramirez-Castillejo C, Sanchez-Sanchez F, Andreu-Agullo C et al. Pigment epithelium-derived factor is a niche signal for neural stem cell renewal. Nat Neurosci 2006; 9: 3319.
  • 8
    Zhang SX, Wang JJ, Gao G et al. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J 2006; 20: 3235.
  • 9
    Stellmach V, Crawford SE, Zhou W et al. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 2001; 98: 25937.
  • 10
    Ek ET, Dass CR, Choong PF. PEDF: a potential molecular therapeutic target with multiple anti-cancer activities. Trends Mol Med 2006; 12: 497502.
  • 11
    Volpert OV, Zaichuk T, Zhou W et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002; 8: 34957.
  • 12
    Zhang SX, Wang JJ, Gao G et al. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 2006; 37: 112.
  • 13
    Ho TC, Chen SL, Yang YC et al. Cytosolic phospholipase A2-α is an early apoptotic activator in PEDF-induced endothelial cell apoptosis. Am J Physiol Cell Physiol 2009; 296: C27384.
  • 14
    Ho TC, Chen SL, Yang YC et al. PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells. Cardiovasc Res 2007; 76: 21323.
  • 15
    Steele FR, Chader GJ, Johnson LV et al. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci USA 1993; 90: 152630.
  • 16
    Garcia M, Fernandez-Garcia NI, Rivas V et al. Inhibition of xenografted human growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res 2004; 64: 563242.
  • 17
    Streck CJ, Zhang Y, Zhou J et al. Adeno-associated virus vector-mediated delivery of pigment epithelium-derived factor restricts neuroblastoma angiogenesis and growth. J Pediatr Surg 2005; 40: 23643.
  • 18
    Zhu B, Lu L, Cai W et al. Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis. Mol Cancer Ther 2007; 6: 3297306.
  • 19
    Wang QS, Yang X, Yang ZH et al. Novel method for expression and purification of human pigment epithelium-derived factor with biological activities in Escherichia coli. Prep Biochem Biotechnol 2006; 36: 12738.
  • 20
    Weidner N, Semple JP, Welch WR et al. Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 18.
  • 21
    Zhang T, Guang YL. Production of active pigment epithelium-derived factor in E. coli. Biotechnol Lett 2005; 27: 4037.
  • 22
    Dawson DW, Volpert OV, Gillis P et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285: 2458.
  • 23
    Duh EJ, Yang HS, Suzuma I et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 2002; 43: 8219.
  • 24
    Wang L, Schmitz V, Perez-Mediavilla A et al. Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther 2003; 8: 729.
  • 25
    Stratikos E, Alberdi E, Gettins PG et al. Recombinant human pigment epithelium-derived factor (PEDF): characterization of PEDF overexpressed and secreted by eukaryotic cells. Protein Sci 1996; 5: 257582.
  • 26
    Sánchez-Sánchez F, Aroca-Aguilar JD, Segura I et al. Expression and purification of functional recombinant human pigment epithelium-derived factor (PEDF) secreted by the yeast Pichia pastoris. J Biotechnol 2008; 134: 193201.
  • 27
    Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 158.
  • 28
    Apte RS, Harbour JW. Inhibiting angiogenesis in retinoblastoma. Ophthalmic Res 2007; 39: 18890.
  • 29
    Poulaki V, Mitsiades CS, McMullan C et al. Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing. Invest Ophthalmol Vis Sci 2005; 46: 35866.
  • 30
    Gao G, Li Y, Gee S et al. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem 2002; 277: 94927.
  • 31
    Gao G, Li Y, Zhang D et al. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 2001; 489: 2706.
  • 32
    Leung DW, Cachianes G, Kuang WJ et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 13069.
  • 33
    Choi YK, Kim JH, Kim WJ et al. AKAP12 regulates human blood-retinal barrier formation by downregulation of hypoxia-inducible factor-1alpha. J Neurosci 2007; 27: 447281.
  • 34
    Jia RB, Zhang P, Zhou YX et al. VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma. Ophthalmic Res 2007; 39: 10815.
  • 35
    Mizokami K, Kakeji Y, Oda S et al. Clinicopathologic significance of hypoxia-inducible factor1 alpha overexpression in gastric carcinomas. J Surg Oncol 2006; 94: 14954.
  • 36
    Yeo EJ, Chun YS, Cho YS et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003; 95: 51625.
  • 37
    Stoeltzing O, McCarty MF, Wey JS et al. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 2004; 96: 94656.
  • 38
    Lu L, Yang Z, Zhu B et al. Kallikrein-binding protein suppresses growth of hepatocellular carcinoma by anti-angiogenic activity. Cancer Lett 2007; 257: 97106.